Redeye returns with its review of BONESUPPORT following its conference call earlier today. Our initial take on the news as being relatively uneventful for its longer-term sales prospects has not been changed. While an approval would manifest its US launch, sending a strong signal to the market with CERAMENT G's introduction, the delay does not change our view of the company's fundamental value. We repeat our Base Case of SEK 90 per share.